etoposide
Showing 1 - 25 of 1,852
Neuroendocrine Carcinoma of the Bladder, Bladder Cancer Trial (Adebrelimab, Etoposide, Cisplatin)
Not yet recruiting
- Neuroendocrine Carcinoma of the Bladder
- Bladder Cancer
- Adebrelimab
- +3 more
- (no location specified)
Oct 14, 2023
Merkel Cell Carcinoma Trial in Milano, Siena, Verona (Pembrolizumab, Etoposide, Cisplatin or Carboplatin)
Not yet recruiting
- Merkel Cell Carcinoma
- Pembrolizumab, Etoposide, Cisplatin or Carboplatin
-
Milano, Italy
- +2 more
Oct 10, 2023
Carcinoma, Cervix Carcinoma Trial in Fuzhou (Karelizumab combined with etoposide and cisplatin)
Not yet recruiting
- Carcinoma
- Cervix Carcinoma
- Karelizumab combined with etoposide and cisplatin
-
Fuzhou, Fujian, ChinaFujian Cancer Hospital
Jun 9, 2023
MGMT-Unmethylated Glioblastoma Trial (Etoposide Plus Cisplatin)
Not yet recruiting
- MGMT-Unmethylated Glioblastoma
- Etoposide Plus Cisplatin
- (no location specified)
Jan 12, 2023
Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant Trial in New York (Etoposide; Oral, 50 Mg, Focused
Recruiting
- Diffuse Intrinsic Pontine Glioma
- Diffuse Midline Glioma, H3 K27M-Mutant
- Etoposide; Oral, 50 Mg
- Focused ultrasound with neuro-navigator-controlled sonication
-
New York, New YorkColumbia University Irving Medical Center
Feb 28, 2023
Autologous Stem Cell Transplantation, Conditioning Trial in Xi'an (modified BEAM, BEAM)
Not yet recruiting
- Autologous Stem Cell Transplantation
- Conditioning
- modified BEAM
- BEAM
-
Xi'an, Shaanxi, ChinaFirst Affiliated Hospital of Xian Jiaotong University
Apr 14, 2023
Mammary Tumors, Human Trial in Tianjin (eutidrone etoposide bevacizumab)
Recruiting
- Mammary Neoplasms, Human
- eutidrone etoposide bevacizumab
-
Tianjin, Tianjin, ChinaYehui Shi
Mar 10, 2023
Small Cell Lung Cancer Extensive Stage Trial (Pembrolizumab, Plinabulin plus Etoposide and Platinum)
Not yet recruiting
- Small Cell Lung Cancer Extensive Stage
- Pembrolizumab, Plinabulin plus Etoposide and Platinum
- (no location specified)
Feb 15, 2023
Toripalimab, First-line Treatment Trial in Guangzhou (EP/EC+PD-1)
Recruiting
- Toripalimab
- First-line Treatment
-
Guangzhou, Guangdong, ChinaSun Yat-sen University cancer center
Mar 7, 2023
Lymphoma Trial in Cairo (BEAM Protocol, CEM protocol)
Recruiting
- Lymphoma
- BEAM Protocol
- CEM protocol
-
Cairo, EgyptInternational Medical Center (IMC) Hospital, Cairo, Egypt.
Apr 1, 2023
HER2-positive Breast Cancer Trial (Tucatinib (Combination of tucatinib-Oral VP16-trastuzumab))
Not yet recruiting
- HER2-positive Breast Cancer
- Tucatinib (Combination of tucatinib-Oral VP16-trastuzumab)
- (no location specified)
Jul 20, 2023
Small Cell Lung Cancer Recurrent Trial in Madrid, Pamplona, Valencia (Debio 0123, Etoposide, Carboplatin)
Not yet recruiting
- Small Cell Lung Cancer Recurrent
- Debio 0123
- +2 more
-
Madrid, Spain
- +3 more
Apr 3, 2023
Germ Cell Tumor, Non-seminomatous Germ Cell Tumor, Ovarian Germ Cell Tumor Trial in Indianapolis (Etoposide)
Recruiting
- Germ Cell Tumor
- +2 more
- Etoposide
-
Indianapolis, IndianaIndiana University Melvin & Bren Simon Cancer Center
Dec 20, 2022
Adrenocortical Carcinoma Trial in Brescia (Etoposide, doxorubicin, cisplatin and Mitotane plus Megestrol Acetate 160 MG,
Recruiting
- Adrenocortical Carcinoma
- Etoposide, doxorubicin, cisplatin and Mitotane plus Megestrol Acetate 160 MG
- Etoposide, doxorubicin, cisplatin and Mitotane plus Placebo
-
Brescia, ItalyAlfredo Berruti
Jun 12, 2023
Small Cell Lung Cancer Trial in Nice (acetazolamide in combination with platinum and etoposide-based radiochemo)
Recruiting
- Small Cell Lung Cancer
- acetazolamide in combination with platinum and etoposide-based radiochemotherapy
-
Nice, FranceCentre Antoine Lacassagne
Jan 19, 2023
Neuroendocrine Tumors Trial (BI 764532, Carboplatin, Etoposide)
Not yet recruiting
- Neuroendocrine Neoplasms
- BI 764532
- +3 more
- (no location specified)
Nov 10, 2023
Hemophagocytic Lymphohistiocytosis Trial in Beijing (Venetoclax, Dexamethasone, Etoposide)
Recruiting
- Hemophagocytic Lymphohistiocytosis
- Venetoclax
- +2 more
-
Beijing, Beijing, ChinaBeijing Friendship Hospital, Capital Medical University
Sep 15, 2022
Progression Free Survival(PFS) Trial (Toposide capsules combined with anrotinib and Emvolizumab group)
Not yet recruiting
- Progression Free Survival(PFS)
- Toposide capsules combined with anrotinib and Emvolizumab group
- (no location specified)
Jan 13, 2023
Neuroendocrine Carcinoma Trial in Wuhan (Surufatinib and Serplulimab)
Not yet recruiting
- Neuroendocrine Carcinoma
- Surufatinib and Serplulimab
-
Wuhan, Hubei, ChinaCancer Center, Union Hospital, Tongji Medical College, Huazhong
Feb 18, 2023
Outcomes ofBrazilian Cohort of Previously Untreated Extensive
Not yet recruiting
- Extensive-stage Small-cell Lung Cancer
- Observational study
- (no location specified)
Aug 24, 2023
NK-T-Cell Lymphoma, Extranodal Trial (Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride
Not yet recruiting
- NK-T-Cell Lymphoma, Extranodal
- Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride and Dexamethasone (P-GEMD) regimen
- (no location specified)
Mar 7, 2023
Extensive Stage Small Cell Lung Cancer Trial (HLX10 + chemo (carboplatin-etoposide), Atezolizumab + chemo
Not yet recruiting
- Extensive Stage Small Cell Lung Cancer
- HLX10 + chemotherapy (carboplatin-etoposide)
- Atezolizumab + chemotherapy (carboplatin-etoposide)
- (no location specified)
Jul 19, 2022
Extensive-stage Small-cell Lung Cancer Trial in China (serplulimab, Cisplatin, Carboplatin)
Not yet recruiting
- Extensive-stage Small-cell Lung Cancer
- serplulimab
- +4 more
-
Shantou, Guangdong, China
- +6 more
Mar 1, 2023
B-cell Non Hodgkin Lymphoma Trial (Odronextamab, Loncastuximab tesirine, Rituximab)
Not yet recruiting
- B-cell Non Hodgkin Lymphoma
- Odronextamab
- +8 more
- (no location specified)
Aug 7, 2023